Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

被引：12
|
作者：
DiNardo, Courtney D. [1 ]
Watts, Justin M. [2 ]
Stein, Eytan M. [3 ]
De Botton, Stephane [4 ]
Fathi, Amir T. [5 ]
Prince, Gabrielle T. [6 ]
Stein, Anthony S. [7 ]
Foran, James M. [8 ]
Stone, Richard M. [9 ]
Patel, Prapti A. [10 ]
Tallman, Martin S. [3 ]
Choe, Sung [11 ]
Wang, Hongfang [11 ]
Zhang, Vickie [11 ]
Dai, David [11 ]
Fan, Bin [11 ]
Yen, Katharine E. [11 ]
Kapsalis, Stephanie M. [11 ]
Hickman, Denice [11 ]
Agresta, Samuel V. [11 ]
Liu, Hua [11 ]
Wu, Bin [11 ]
Attar, Eyal C. [11 ]
Kantarjian, Hagop M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Inst Gustave Roussy, Villejuif, France
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] City Hope Med Ctr, Duarte, CA USA
[8] Mayo Clin, Jacksonville, FL 32224 USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[11] Agios Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111264
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1812
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Kurman, Michael R.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Alvarado, Yesid
    Naqvi, Kiran
    Ravandi, Farhad
    Jabbour, Elias J.
    Delumpa, Ricardo
    Madden, Timothy
    Maier, Gary
    Iwamura, Hiroyuki
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [42] A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Watts, Justin M.
    Baer, Maria R.
    Lee, Sangmin
    Yang, Jay
    Dinner, Shira Naomi
    Prebet, Thomas
    Schiller, Gary J.
    Seiter, Karen
    Ferrell, Paul Brent
    Kelly, Patrick Francis
    Li, Ping
    Sweeney, Jennifer
    Watson, Courtney
    Mohamed, Hesham
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] A First-in-Human, Phase 1, Dose Escalation Study of Sgr-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
    DiNardo, Courtney D.
    Strickland, Stephen Anthony
    Skikne, Barry
    Zeidan, Amer M.
    Traer, Elie
    Carraway, Hetty E.
    Frankel, Stanley
    Weiss, Daniel E.
    Wang, Jacky H.
    Pirie-Shepherd, Steven
    Piccotti, Joseph
    Wright, D. Hamish
    Akinsanya, Karen
    BLOOD, 2023, 142
  • [44] Ivosidenib in Chinese patients (pts) with relapsed/refractory acute myeloid leukemia (R/R AML) with an IDH1 mutation: Results from a bridging registrational study
    Wang, J.
    Jin, J.
    Yin, Q.
    Sun, M.
    Liang, Y.
    Chang, C.
    Zheng, J.
    Li, J.
    Ji, C.
    Zhang, J.
    Li, J.
    Gong, Y.
    Luo, S.
    Zhang, Y.
    Chen, R.
    Shen, Z.
    Yu, X.
    Liu, K.
    Yang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S773 - S773
  • [45] MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study
    Assouline, Sarit
    Chang, Julie
    Rifkin, Robert
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Xi, Yingmei
    Di Bacco, Alessandra
    Martin, Peter
    BLOOD, 2011, 118 (21) : 1148 - 1148
  • [46] Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
    Woyach, Jennifer
    Stephens, Deborah M.
    Flinn, Ian W.
    Bhat, Seema A.
    Savage, Ronald E.
    Chai, Feng
    Eathiraj, Sudharshan
    Granlund, Lindsey
    Szuszkiewicz, Lyndsey A.
    Schwartz, Brian
    Byrd, John C.
    BLOOD, 2019, 134
  • [47] Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
    Richardson, Paul G.
    Baz, Rachid
    Wang, Luhua
    Jakubowiak, Andrzej J.
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandri
    Hui, Ai-Min
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 140 - 140
  • [48] Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
    Dinner, Shira N.
    Dunn, Tamara J.
    Medeiros, Bruno C.
    Coutre, Steven E.
    Berube, Caroline
    Gotlib, Jason
    Liedtke, Michaela
    BLOOD, 2012, 120 (21)
  • [49] A phase 1/2a, dose-escalation and dose-expansion study of ZX-101A in patients with relapsed/resistant or refractory advanced hematologic malignancies.
    Qin, Xiaoli
    Bautista, Edgar
    Teitelbaum, April
    Hao, Xiaolin
    Yang, Jinfu
    CANCER RESEARCH, 2021, 81 (13)
  • [50] Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
    Kumar, Shaji
    Bensinger, William I.
    Reeder, Craig B.
    Zimmerman, Todd M.
    Berenson, James R.
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Niesvizky, Ruben
    BLOOD, 2011, 118 (21) : 371 - 372
12345